The Central Social Insurance Medical Council, better known as Chuikyo, appears to see the need to set up new dosage…
REGULATORY
Kato Repeats May-End Goal for Avigan OK, Negative for Use in Mildly Ill Patients
Health Minister Katsunobu Kato on May 8 reiterated the government’s goal to grant approval for Fujifilm’s antiviral Avigan (favipiravir) for the treatment of COVID-19 by the end of May, while sounding negative about its use in mildly ill patients who…
To read the full story
Related Article
- Avigan Interim Analysis Not Intended to Determine Efficacy, Research Sponsor Says on Reports
May 21, 2020
- Japan Eyes May Approval for Avigan with Investigator-Led Study Data
May 7, 2020
- Japan Can’t Give “Special Approval” for Avigan under Current Law: Abe
April 30, 2020
- CMIC Group to Support Clinical Trial, Manufacturing of Avigan for COVID-19 Treatment
April 24, 2020
- Fujifilm Starts Boosting Avigan Production for COVID-19
April 16, 2020
- Health Minister Vows to Shorten Review Time for Avigan
April 14, 2020
- Sanofi Launches Kevzara Trial for Severe COVID-19 in Japan
April 10, 2020
- Fujifilm to Start PII Avigan Trial for COVID-19 in US
April 10, 2020
- Fujifilm Launches Avigan Trial with Completion Eyed in June; Sanofi Too to Test Kevzara in Japan
April 1, 2020
- Fujifilm Wants to Launch Avigan Trial in Japan by End of This Week, Abe Talks to WHO Chief
March 31, 2020
- PM Abe Says Japan to Start Registration Trial for Avigan for COVID-19, Plans Production Boost
March 30, 2020
- Japan Plans Alvesco Clinical Trial for Coronavirus
March 24, 2020
- Chugai Mulling Japan Actemra Trial for COVID-19; Sanofi Says No Kevzara Plan for Now
March 24, 2020
- Japan’s Avigan Stockpile for Some 2 Million People; No Plan for Increase: Govt
March 18, 2020
- Fujifilm Plans Company-Sponsored Avigan Trial for COVID-19 in Japan
March 17, 2020
- Sanofi Exploring Kevzara Use for Novel Coronavirus
March 13, 2020
- Fujifilm Receives Avigan Supply Requests from Overseas amid Coronavirus Outbreak
February 27, 2020
REGULATORY
- MHLW Proposes Tightening 40% Entry Pricing for New Oral Generics
November 30, 2023
- Lawmakers Request 4-Valent HPV Vaccination Program for Males to Minister
November 30, 2023
- MHLW Pushes Boosted Launch Premiums, Slew of Other Pricing Steps to Reward Innovation
November 30, 2023
- No Consensus on PMP Company Criteria, Likely Review for Spillover Rule: Chuikyo
November 30, 2023
- Panelists Urge Exclusion of LLPs from Copay Increase If Generic Access Is Difficult
November 30, 2023
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…